News Headlines

  1. Matica Bio Secures Commercial Manufacturing Deal With U.S. Biotech Company 9/15/2025

    Matica Biotechnology, Inc. (Matica Bio), a leading contract development and manufacturing organization (CDMO) specializing in viral vector manufacturing for cell and gene therapies, today announced a strategic commercial manufacturing agreement with a clinical-stage biotech company based in the United States.

  2. Abzena Enhances AbZelectPRO™ Cell Line Offering With New GS Knockout Platforms 9/15/2025

    Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, announced the expansion of its AbZelectPRO™ cell line development (CLD) platform with the launch of two next-generation Glutamine Synthetase ("GS") knockout CHO-K1 expression systems, including a double knockout ADCC+ platform for afucosylated proteins.

  3. Thermo Fisher Scientific Launches Efficient-Pro Medium (+) Insulin For Enhanced Bioprocessing Performance 9/15/2025

    Thermo Fisher Scientific Inc., the world leader in serving science, today unveiled the Gibco Efficient-Pro Medium (+) Insulin, a next-generation medium designed to increase titers to maximize productivity and elevate the performance of insulin-dependent CHO cell lines.

  4. CAI Appoints Jamie Robertson As Vice President Of Mission Critical To Drive Innovation And Operational Excellence Across Global Infrastructure Projects 9/14/2025

    CAI, a global leader in operational readiness and excellence for high-stakes, regulated environments, is proud to announce the appointment of Jamie Robertson as Vice President of Mission Critical.

  5. Results Of Nanoform Collaborative Study To Be Presented At U.S. Drug Delivery & Formulation (DDF) Summit 9/11/2025

    Nanoform, a leading nanoparticle medicine performance-enhancing company, announced that key findings from two studies conducted in collaboration between Nanoform and Takeda will be presented at the 15th American Drug Delivery & Formulation Summit (DDF) in Boston, Mass., on September 16, 2025, at 09:10 – 09:40 in Room 1.

  6. Cellectar Biosciences And ITM Enter Supply Agreement For GMP-Grade Actinium-225 9/11/2025

    Cellectar Biosciences, Inc. (Nasdaq: CLRB, “Cellectar”), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, and ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced a supply agreement for Actinium-225 (Ac-225). The agreement will support the clinical development of Cellectar’s actinium-labeled phospholipid ether (PLE) radiopharmaceutical candidates, including its Phase 1-ready compound, CLR 121225, for the treatment of solid tumors.

  7. Charles River Collaborates To Enhance Oncology Manufacturing Portfolio, Advancing Research And Development Of Cell and Gene Therapies To Treat Cancer 9/11/2025

    Charles River Laboratories International, Inc. has recently announced two strategic collaborations across its contract development and manufacturing organization (CDMO), aimed at advancing novel oncology research and development. These collaborations include forming an alliance with the Parker Institute for Cancer Immunotherapy and supporting a streamlined manufacturing process for Children’s Hospital Los Angeles’ Phase I Clinical Trials.

  8. Cytiva And WhiteLab Genomics Team Up To Use AI To Accelerate Cell Line Development 9/10/2025

    Cytiva, a Danaher company and a global leader in the life sciences industry, and WhiteLab Genomics, a techbio company specializing in artificial intelligence for genomic medicine research and development, announced a collaboration to accelerate the development of next-generation genomic medicines.

  9. Symeres Acquires DGr Pharma To Enhance Regulatory Expertise And Broaden Its Biopharma Capabilities 9/10/2025

    Symeres, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announces the acquisition of DGr Pharma, a drug development-focused consultancy, to expand its integrated early-stage drug development services and accelerate IND-enabling capabilities for biopharma clients.

  10. NKGen Biotech, Inc. Announces Completion Of NKMax Co., Ltd. Acquisition; Gains Full Control Of Global Manufacturing And Intellectual Property Assets 9/9/2025

    NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the successful completion of its acquisition of a majority equity stake in NKMax Co., Ltd. (“NKMax”), a Korean biotechnology company, out of bankruptcy.